On July 23, 2023, the enrollment of all cases of coated blood flow guided dense mesh stent, sponsored by Sinomed Neurovita Technology Inc., were successfully completed under the guidance of Professor Zhang Hongqi of Neurosurgery, Xuanwu Hospital of Capital Medical University.
The project was officially launched on March 22, 2023, with the participation of more than ten well-known neurological intervention departments in China. All cases were included in the study and only took 4 months. As the CRO for this study, Links is honored to be involved in this project. During the project process, LINKS actively responded to the needs of all parties and fully promoted the progress of the project.
In the future, we will continue to provide the highest quality service to customers, and accelerate the process of product marketization with the most professional attitude and efficient response speed.
LINKS CRO
As a CRO company providing clinical trial services. LINKS CRO focus on innovation, high-risk implantation(intervention) medical device, with one-stop clinical trial solutions for the whole process of medical device research and development.The headquarters of LINKS is based in Shanghai, with subsidiary branches in Beijing, Shanghai, Guangzhou, and Shenzhen, in addition to ten regional offices. The current workforce comprises almost 200 employees, with technical personnel making up over 85% and dispersed across almost 30 cities nationwide.
Key Services include CRO, SMO, CER, Audit, Post-market research, core laboratory registration both domestically and overseas, innovation declaration, Expert Consultancy, and overseas enterprise agency services.
Key Indications include Cardiovascular, Neurovascular, Peripheral Vascular, Surgery Robot, Oncology, Ophthalmology, Medical Cosmetology, and other fields such as orthopedics. There are almost 300 projects consultations and services by LINKS each year.
